GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Friday, 11 Jul 2014 | 10:30 AM ET

    Amgen Inc. rose$. 37 or. 3 percent, to $119.32. Biogen Idec fell $1.42 or. 4 percent, to $317.70. Celgene Corp. fell$. 05 or. 1 percent, to $87.78.

  • Midday Glance: Biotechnology companies Thursday, 10 Jul 2014 | 1:44 PM ET

    Amgen Inc. fell$. 81 or. 7 percent, to $118.76. Biogen Idec fell$. 39 or. 1 percent, to $319.75. Celgene Corp. rose$. 72 or. 8 percent, to $88.24.

  • Early Glance: Biotechnology companies Thursday, 10 Jul 2014 | 11:01 AM ET

    Amgen Inc. fell$. 89 or. 7 percent, to $118.68. Biogen Idec fell $3.10 or 1.0 percent, to $317.04. Celgene Corp. fell$. 60 or. 7 percent, to $86.92.

  • Midday Glance: Biotechnology companies Tuesday, 8 Jul 2014 | 1:41 PM ET

    Amgen Inc. rose$. 06 or percent, to $120.22. Biogen Idec fell $7.60 or 2.3 percent, to $318.08. Celgene Corp. fell $3.01 or 3.4 percent, to $85.86.

  • Early Glance: Biotechnology companies Tuesday, 8 Jul 2014 | 10:30 AM ET

    Amgen Inc. fell$. 10 or. 1 percent, to $120.06. Biogen Idec fell $4.43 or 1.4 percent, to $321.25. Celgene Corp. fell $1.39 or 1.6 percent, to $87.48.

  • Final Glance: Biotechnology companies Thursday, 3 Jul 2014 | 5:15 PM ET

    Amgen Inc. rose $1.82 or 1.5 percent, to $122.85. Biogen Idec rose$. 15 or percent, to $331.15. Celgene Corp. rose$. 12 or. 1 percent, to $90.19.

  • Midday Glance: Biotechnology companies Thursday, 3 Jul 2014 | 1:17 PM ET

    Amgen Inc. rose $1.82 or 1.5 percent, to $122.85. Biogen Idec rose$. 15 or percent, to $331.15. Celgene Corp. rose$. 12 or. 1 percent, to $90.19.

  • Early Glance: Biotechnology companies Thursday, 3 Jul 2014 | 10:30 AM ET

    Amgen Inc. fell$. 15 or. 1 percent, to $120.88. Biogen Idec fell $1.90 or. 6 percent, to $329.10. Celgene Corp. fell$. 79 or. 9 percent, to $89.28.

  • July 2- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

  • *Shire rejects AbbVie offer valued at 46.26 pounds a share. LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into lower tax rates abroad via an acquisition.

  • LONDON, June 20- British drugmaker Shire has rejected a 27 billion-pound takeover offer from AbbVie, the latest attempt by a U.S. healthcare firm to tap into the London- listed group's low tax rate. Abbvie's takeover offer proposed creating a new U.S.-listed holding company with a UK tax domicile in a so-called "inversion" move.

  • *Shire expecting to receive approaches, taps Citi- sources. LONDON, June 17- Shares in Shire hit a record high on Tuesday on expectations of a takeover as dealmaking sweeps the drugs sector, after Reuters reported the group had hired investment bank Citi as a defence adviser. Shire and Citi declined to comment.

  • LONDON, June 16- London- listed drugmaker Shire has hired investment bank Citi as an adviser, expecting to receive takeover approaches following a wave of deals in the healthcare sector, sources familiar with the matter told Reuters.

  • CHICAGO, June 6- A new way of evaluating tumors may soon help cancer patients identify the underlying genetic link to their disease- and the best possible treatment- all in a single test. "We really are moving away from this one drug, one biomarker, one companion diagnostic," said Dr Richard Pazdur, the U.S. Food and Drug Administration's oncology chief.

  • FRANKFURT, May 23- U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen said.

  • May 23- For two months last summer, Stanford Law School professor Joseph Grundfest locked himself away in his home office in California's Portola Valley.

  • Rally or not, these industries are in a correction Wednesday, 21 May 2014 | 12:47 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks may be rallying Wednesday, but there are still plenty of industries that have lost substantial ground.

  • *Sanofi has restructured R&D, has strong pipeline-Zerhouni. PARIS, May 15- France's Sanofi has strengthened its drug pipeline and has enough future blockbusters lined up for it to steer clear of the M&A frenzy "overheating" the industry, the drugmaker's R&D chief told Reuters.

  • *$106 bln Pfizer bid stirs up political storm on job fears. LONDON, May 11- How British is AstraZeneca? With a French chief executive, Swedish chairman, 40 percent of its sales in the United States and 87 percent of its staff overseas, the answer is not simple.

  • Lightning Round: Noodles & Co., TriNet & More Thursday, 8 May 2014 | 6:44 PM ET

    It's time for the Lightning Round. Cramer makes the call on viewer favorites.